ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2023年03月02日 12時00分
Source:
Eisai
バイオジェン・ジャパンとエーザイの日本における多発性硬化症治療剤の共同販促について
東京, 2023年03月02日 - (JCN Newswire) - バイオジェン・ジャパン株式会社(本社:東京都、代表取締役社長:傳 幸諭、以下 バイオジェン・ジャパン)とエーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下エーザイ)は、2018年1月より実施していたバイオジェン・ジャパンの多発性硬化症治療剤「テクフィデラ(R)」(一般名:フマル酸ジメチル)、「タイサブリ(R)」(一般名:ナタリズマブ(遺伝子組換え))、「アボネックス(R)」(一般名:インターフェロンベーター1a(遺伝子組換え))に関する日本における共同販促契約を2023年3月末日をもって終了することをお知らせします。
これまで両社共同で情報提供活動を行ってきましたが、当該製品の市場浸透について一定の目的を達成したことから、両社合意の下、本共同販促契約を終了することとなりました。本共同販促契約の終了に伴い、両社による引継ぎ期間を経て、バイオジェン・ジャパンが、当該製品に関するすべての業務を行うこととなります。また、本共同販促契約の終了にあたり、バイオジェンはエーザイに31 million USDを支払います。
なお、本件はバイオジェンとエーザイの間の他の契約には影響しません。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2023/news202315.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hitachi High-Tech and NOF Metal Coatings use materials informatics to improve the efficiency and sophistication of research and development work
Aug 19, 2025 16:38 JST
NEC and ClimateAi Develop Conceptual Model to Promote Climate Change Adaptation in Agriculture
Aug 19, 2025 11:33 JST
Value Research Center to host The Valuism Conference 2025 on August 28-29 (Hybrid Format)
Aug 19, 2025 11:00 JST
Fujitsu signs new licensing agreement with Palantir
Aug 19, 2025 10:55 JST
The 35th Food Expo and concurrent fairs attract over 500,000 visits
Aug 18, 2025 21:07 JST
Team Mitsubishi Ralliart Triumphs at Asia Cross Country Rally 2025 with Chayapon Yotha's Overall Victory and Team Award
Aug 18, 2025 15:22 JST
UNFPA and NEC Collaborate to Build Beneficiary Information Management and e-Voucher System
Aug 18, 2025 14:38 JST
Anime Tokyo Station Surpasses 200,000 Visitors
Aug 18, 2025 11:00 JST
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
Aug 18, 2025 09:11 JST
TANAKA Holds Press Conference to Commemorate Its 140th Anniversary
Aug 15, 2025 03:00 JST
Mitsubishi Corporation to acquire shares in Copper World copper mine project in the US
Aug 14, 2025 12:05 JST
Team Mitsubishi Ralliart Conducts Shakedown Ahead of Asia Cross Country Rally 2025: Targeting First Overall Championship in Three Years
Aug 07, 2025 18:40 JST
Toyota to Establish New Vehicle Manufacturing Plant in Japan
Aug 07, 2025 18:31 JST
MHI Heat Pumps NZ Wins People's Choice Award for Third Year Running
Aug 07, 2025 17:32 JST
FWD Group completes build-out of high-net-worth hub in Asia
Aug 07, 2025 14:00 JST
Shoucheng Highlights VC Role and Robot Lineup at WRC 2025
Aug 07, 2025 10:50 JST
Fastport eQuad, Flagship Product from New Honda Business Venture, Wins "Red Dot: Best of the Best 2025" Award in Red Dot Award: Design Concept
Aug 06, 2025 19:40 JST
Dream Incubator and DENSO Launch Demonstration Project for Digital Platform Development for Mobility Circular Economy and Integrated Manufacturing for India
Aug 06, 2025 18:54 JST
Fujitsu's CHRO Roundtable Report 2025 highlights data-driven HRBP practices for human capital management
Aug 06, 2025 11:00 JST
MHI Selected to Enter Next Stage Procurement Process for Australia's New General-Purpose Frigates
Aug 05, 2025 22:02 JST
More Latest Release >>
Related Release
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
8/18/2025 9:11:00 AM JST
Revenue of LEQEMBI(R) (Preliminary Basis)
7/31/2025 6:27:00 PM JST
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
7/31/2025 9:30:00 AM JST
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
7/31/2025 9:20:00 AM JST
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
7/31/2025 9:10:00 AM JST
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
7/29/2025 9:01:00 AM JST
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
7/25/2025 1:31:00 PM JST
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
7/23/2025 10:07:00 AM JST
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
7/22/2025 11:56:00 AM JST
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
7/16/2025 2:50:00 PM JST
More Press release >>